Navigation Links
Avanir Pharmaceuticals Cancels Previously Scheduled Earnings Call
Date:12/6/2014

ALISO VIEJO, Calif., Dec. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that, as a result of the entry by Avanir Pharmaceuticals into an agreement and plan of merger with Otsuka Pharmaceutical Co., Ltd., and Bigarade Corporation, a wholly owned subsidiary of Otsuka Pharmaceutical, on December 1, 2014, Avanir Pharmaceuticals is cancelling its previously scheduled Fiscal 2014 Fourth Quarter Financial Results and Conference Call.

Avanir Pharmaceuticals plans to file its Annual Report on Form 10-K for the fiscal year ended September 30, 2014 on or by December 15, 2014.

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward-Looking Statements
The statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "seek," "plan," "expect," "should," "would" or similar expressions are intended to identify forward-looking statements. These forward-looking statements include without limitation statements regarding the planned completion of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 1, 2014, by and among Avanir Pharmaceuticals, Inc. ("Avanir"), Otsuka Pharmaceutical Co., Ltd. ("Otsuka") and Bigarade Corporation ("Acquisition Sub"). Risks and uncertainties that could cause results to differ from expectations include: uncertainties as to the timing of the tender offer and the merger; uncertainties as to the percentage of Avanir stockholders tendering their shares in the tender offer; the possibility that competing offers will be made; the possibility that various closing conditions for the tender offer or the merger may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the merger; the effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, vendors and other business partners; the risk that stockholder litigation in connection with the tender offer or the merger may result in significant costs of defense, indemnification and liability; and risks and uncertainties pertaining to the business of Avanir, including the risks and uncertainties detailed in Avanir's public periodic filings with the Securities and Exchange Commission (the "SEC"), as well as the tender offer materials to be filed by Otsuka and Acquisition Sub and the Solicitation/Recommendation Statement to be filed by Avanir in connection with the tender offer.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Avanir undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Notice to Investors
The tender offer described above has not yet commenced. This communication is not an offer to buy nor a solicitation of an offer to sell any securities of Avanir. The solicitation and the offer to buy shares of the Avanir's common stock will only be made pursuant to a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that Otsuka and Acquisition Sub intend to file with the SEC. In addition, Avanir will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. Once filed, investors will be able to obtain the tender offer statement on Schedule TO, the offer to purchase, the Solicitation/Recommendation Statement of Avanir on Schedule 14D-9 and related materials with respect to the tender offer and the merger, free of charge at the website of the SEC at www.sec.gov, and from the information agent named in the tender offer materials. Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by Avanir under the "Investors" section of Avanir's website at www.avanir.com. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE, INCLUDING THE SOLICITATION/RECOMMENDATION STATEMENT OF AVANIR AND ANY AMENDMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE TENDER OFFER AND THE MERGER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES INTO THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

 

 

Logo - http://photos.prnewswire.com/prnh/20130207/LA55901LOGO


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of Avanir Pharmaceuticals, Inc.
2. SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Avanir Pharmaceuticals, Inc. in Connection with the Sale of the Company -AVNR
3. Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA
4. Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine
5. Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimers Disease at the American Neurological Association Meeting
6. Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Associations (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimers Disease
7. Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
8. Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock
10. The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead
11. Technical Snapshot on Pharma Stocks - Allergan, Akorn, Mallinckrodt, Mylan, and AVANIR Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2020)... (PRWEB) , ... May 14, 2020 , ... ... discuss sEMG Biofeedback as an effective intervention tool in neuro-rehabilitation. sEMG Biofeedback is ... will show the immediate effect of using biofeedback to create awareness and efficient ...
(Date:5/14/2020)... ... 2020 , ... Northern Quinoa Production Corporation ( NorQuin ) ... ingredient suppliers, Ingredion Incorporated , which will distribute NorQuin's high-value ... , NorQuin has invested more than two decades of research to ...
(Date:5/11/2020)... ... May 11, 2020 , ... ... people worldwide. Recommendations to improve immunity often include social distancing, enhanced hygiene, adequate ... Michael T. Murray, N.D., also stresses the importance of digestive enzymes in boosting ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... May 21, 2020 , ... A new report ... Group, details over 90 companies involved in the point of care test industry. ... for preliminary testing, COVID-19 has made point-of-care more important than in the past, according ...
(Date:5/17/2020)... ... 2020 , ... R3 Stem Cell International is now offering ... are two program options for patients and their families, which are all inclusive ... exactly what causes Autism Spectrum Disorder (ASD), there are several recent clinical studies ...
(Date:5/16/2020)... (PRWEB) , ... May 15, 2020 , ... On May 21, T1V will host a ... Ellison Institute of USC, and a contributor to CBS news, as we address COVID-19 and ... place in most parts of the country since March, many questions are left unanswered as ...
(Date:5/16/2020)... HOWELL, Mich. (PRWEB) , ... May 16, 2020 , ... ... be caught relatively early, this will prevent permanent arthritis from developing. This can keep ... , Dr. Biernacki further states “It is estimated that the people who develop flat ...
(Date:5/15/2020)... ... May 15, 2020 , ... Collagen has taken the ... natural channel alone in 2019, according to a 2020 Nutritional Outlook ‘Ingredients to Watch’ ... further and further away from the high molecular weight, low-impact products of the past ...
Breaking Medicine News(10 mins):